According to market research study published by Gen Consulting Company, the global embolotherapy market is expected to reach approximately USD 4,794 million, representing a CAGR of 6.5% during the forecast period 2022-2028.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global embolotherapy market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the embolotherapy industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, indication, procedure, end user, and region. The global market for embolotherapy can be segmented by product: embolic agents, support devices. Among these, the embolic agents segment was accounted for the highest revenue generator in 2021. Embolotherapy market is further segmented by indication: cancer, neurological diseases, peripheral vascular diseases, urological and nephrological disorders, gastrointestinal disorders. The cancer segment is estimated to account for the largest share of the global embolotherapy market. Based on procedure, the embolotherapy market is segmented into: trancatheter arterial embolization (TAE), transarterial chemoembolization (TACE), transarterial radioembolization (TARE). The trancatheter arterial embolization (TAE) segment held the largest share of the global embolotherapy market in 2021 and is anticipated to hold its share during the forecast period. On the basis of end user, the embolotherapy market also can be divided into: hospitals and clinics, ambulatory surgical centers (ASCs), others. In 2021, the hospitals and clinics segment made up the largest share of revenue generated by the embolotherapy market. Embolotherapy market by region is categorized into: Asia Pacific, Europe, North America, Rest of the World (RoW).

By product:
– embolic agents
– support devices

By indication:
– cancer
– neurological diseases
– peripheral vascular diseases
– urological and nephrological disorders
– gastrointestinal disorders

By procedure:
– trancatheter arterial embolization (TAE)
– transarterial chemoembolization (TACE)
– transarterial radioembolization (TARE)

By end user:
– hospitals and clinics
– ambulatory surgical centers (ASCs)
– others

By region:
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)

The market research report covers the analysis of key stake holders of the global embolotherapy market. Some of the leading players profiled in the report include Acandis GmbH, Balt Extrusion SAS, Boston Scientific Corporation, Cook Group Incorporated, Guerbet SA, Johnson & Johnson, Kaneka Corporation, Medtronic plc, Meril Life Sciences Private Limited, Merit Medical Systems Inc., Penumbra, Inc., Sirtex Medical Limited, Stryker Corporation, Terumo Corporation, among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report
– To analyze and forecast the market size of the global embolotherapy market.
– To classify and forecast the global embolotherapy market based on product, indication, procedure, end user, region.
– To identify drivers and challenges for the global embolotherapy market.
– To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global embolotherapy market.
– To identify and analyze the profile of leading players operating in the global embolotherapy market.

Why Choose This Report
– Gain a reliable outlook of the global embolotherapy market forecasts from 2022 to 2028 across scenarios.
– Identify growth segments for investment.
– Stay ahead of competitors through company profiles and market data.
– The market estimate for ease of analysis across scenarios in Excel format.
– Strategy consulting and research support for three months.
– Print authentication provided for the single-user license.